• Krystal Biotech recently reported first-quarter 2026 results, with net income rising to US$55.93 million and diluted EPS from continuing operations reaching US$1.83, and it also secured FDA approval for at-home use of Vyjuvek for dystrophic epidermolysis bullosa patients.
• These stronger earnings and expanded Vyjuvek administration options, alongside a high-profile appearance at the upcoming BofA Securities Health Care Conference, highlight how Krystal Biotech is pairing commercial progress with increased investor engagement.
• Next, we’ll examine how Vyjuvek-driven earnings strength and new at-home treatment flexibility influence Krystal Biotech’s existing investment narrative.

The latest GPUs need a type of rare earth metal called Terbium and there are only 33 companies in the world exploring or producing it. Find the list for free.

Krystal Biotech Investment Narrative Recap

To own Krystal Biotech, you need to believe Vyjuvek can support a profitable rare disease franchise while the broader gene therapy pipeline matures. The latest US$55.93 million Q1 net income and at home Vyjuvek approval support that story, but they do not remove the near term risk that revenues remain concentrated in a single product with potentially uneven treatment patterns, nor do they resolve dependence on timely, favorable reimbursement outcomes in Europe and Japan.

The most directly relevant update is the FDA approval of at home Vyjuvek administration for dystrophic epidermolysis bullosa. This change may help smooth some of the treatment “waviness” by giving patients and caregivers more flexibility, which could be important as Krystal continues international rollouts where home or clinic dosing is also allowed. How much this actually stabilizes revenue and earnings remains uncertain and will likely be a key focus in upcoming investor discussions.

Yet alongside these positives, investors should be aware that revenue still leans heavily on Vyjuvek and...

Krystal Biotech's narrative projects $987.9 million revenue and $571.3 million earnings by 2029. This requires 36.4% yearly revenue growth and about a $366.5 million earnings increase from $204.8 million today.

Uncover how Krystal Biotech's forecasts yield a $315.00 fair value, a 6% upside to its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were already projecting roughly US$1.4 billion in 2029 revenue and US$947.2 million in earnings, so compared with the baseline focus on reimbursement risk and revenue “waviness,” you can see how far expectations can stretch and why this update may shift both bullish and cautious views over time.

Explore 6 other fair value estimates on Krystal Biotech - why the stock might be worth 19% less than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Krystal Biotech research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Krystal Biotech research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Krystal Biotech's overall financial health at a glance.

Looking For Alternative Opportunities?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.